12:00 AM
 | 
Feb 07, 2000
 |  BC Week In Review  |  Company News  |  Deals

Arena, Fujisawa deal

The companies will validate orphan G protein-coupled receptors (GPCR) as drug screening targets using Arena's CART technology that identifies GPCR modulators. Arena will characterize...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >